At the 2025 JP Morgan Healthcare Conference, GoodRx’s recently appointed CEO Wendy Barnes highlighted the company’s strategic position to address the gaps in the US healthcare landscape.
Referring to these gaps as “white space,” Barnes emphasised GoodRx’s ability to bridge the divide between pharmaceutical manufacturers, pharmacies, pharmacy benefit managers (PBMs), and healthcare providers. This fragmented ecosystem often results in misaligned incentives, complicating access to affordable medication for patients.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataGoodRx operates as a healthcare platform that tracks prescription drug prices and provides consumers with coupons to cut medication costs. During the company’s session on 15 January at JP Morgan, Barnes expressed confidence in the company’s potential to leverage its position amid these complexities: “I cannot think of a better time to be able to influence all of that white space.”
Barnes’ comments come at a critical time for the pharmaceutical industry, with drug price increases once again making headlines. Data from healthcare research company 3 Axis Advisors shows that more than 250 branded drugs saw price hikes this month, with most increases staying under 10% and a median rise of 4.5%. This aligns with data from GlobalData’s Price Intelligence (POLI), which found an average increase of 4% in branded drug prices during the same period.
Over the past few years, legislative measures have sought to address these issues. The Inflation Reduction Act (IRA) has introduced penalties for pharmaceutical companies raising drug prices above the inflation rate, with additional provisions allowing Medicare to negotiate drug prices for the first time and capping out-of-pocket expenses for Medicare beneficiaries at $2,000 annually. Despite these reforms, rising drug prices remain a contentious issue, and President-elect Donald Trump has pledged further action to reduce costs.
GoodRx has positioned itself as a key player in addressing affordability through partnerships and innovative pricing initiatives. For example, the company partnered with Novo Nordisk to provide discounts on the diabetes and weight-loss drugs Ozempic (semaglutide) and Wegovy (semaglutide), which have seen soaring demand. Prescription fills for these glucagon-like peptide-1 receptor agonists (GLP-1RAs), known for appetite suppression and blood sugar regulation, more than doubled in 2024, according to data released by GoodRx.
In another partnership, GoodRx collaborated with Boehringer Ingelheim in July 2024 to offer a low cash price for adalimumab-adbm, a biosimilar to AbbVie’s autoimmune blockbuster Humira. Available to anyone with a valid prescription, regardless of insurance coverage, this initiative aims to reduce time-to-therapy delays for patients with conditions such as rheumatoid arthritis and Crohn’s disease.
GoodRx’s chief financial officer Karsten Voermann highlighted the company’s rapid growth at JP Morgan 2025, from $17m to $18m in revenue in 2020 to $110m in 2024, driven by always-on access and cash pay programmes.
“As we move to these always-on type programmes, we continue to be highly confident that the growth rates we have showcased historically are also the ones that will manifest forward,” Voermann said.
